When combined with previous studies, our pharmacological studies demonstrate that disruption of breast cancer- and RANKL-induced IKKβ activity in cells of the bone metastatic microenvironment resulted in pro-bone gain and anti-bone loss network of effects. Here, TNFSF11 is linked to breast cancer.